Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece
Crossref DOI link: https://doi.org/10.1007/s00296-015-3253-x
Published Online: 2015-03-21
Published Print: 2015-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Athanasakis, Kostas
Tarantilis, Filippos
Tsalapati, Konstantina
Konstantopoulou, Thomais
Vritzali, Eleni
Kyriopoulos, John
Text and Data Mining valid from 2015-03-21